Bleeding Disorder Testing Market Report 2026

The bleeding disorder testing market size has grown strongly in recent years. It will grow from $16.18 billion in 2025 to $17.46 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increasing prevalence of inherited bleeding disorders, wider adoption of laboratory diagnostics, availability of coagulation analyzers, growth of hospital diagnostic services, rising clinical awareness of bleeding disorders.

The bleeding disorder testing market size is expected to see strong growth in the next few years. It will grow to $23.54 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing demand for rapid diagnostic solutions, expansion of personalized medicine approaches, growing investments in diagnostic automation, rising adoption of point-of-care testing, integration of ai-driven diagnostic analytics. Major trends in the forecast period include advancements in coagulation testing accuracy, growing use of point-of-care diagnostic devices, rising adoption of automated blood analyzers, expansion of genetic testing for bleeding disorders, enhanced integration of digital lab systems.

The growing number of clinical trials is anticipated to drive the expansion of the bleeding disorder testing market in the coming years. Clinical trials are research studies designed to evaluate the safety and effectiveness of new medical treatments, therapies, drugs, or technologies in humans. The rise in clinical trials is attributed to advancements in medical research, increased investment in healthcare innovation, and a higher demand for novel treatments and therapies. Bleeding disorder testing plays a critical role in clinical trials by assessing the efficacy and safety of new drugs and therapies for bleeding disorders, determining how effectively these treatments manage or correct clotting abnormalities, and monitoring patient responses to ensure optimal dosing and outcomes. For example, according to ClinicalTrials.gov, a US-based clinical trial registry, approximately 477,228 clinical trials were registered by the end of 2023, up from 437,507 in 2022. Consequently, the increasing number of clinical trials is fueling growth in the bleeding disorder testing market.

Key companies in the bleeding disorder testing market are concentrating on developing innovative products, such as gene therapy for Hemophilia B, to deliver long-term solutions, cure genetic bleeding disorders, improve treatment outcomes, and broaden their market presence. Hemophilia B is a bleeding disorder characterized by a deficiency in clotting factor IX, which is vital for proper blood coagulation. Gene therapy for Hemophilia B is an emerging approach aimed at providing a long-lasting solution by addressing the underlying genetic defect causing the condition. For instance, in February 2023, CSL Limited, an Australia-based biotechnology company, received conditional marketing authorization (CMA) from the European Commission for HEMGENIX, the first and only one-time gene therapy for severe and moderately severe hemophilia B. This single treatment is intended to offer prolonged efficacy, potentially reducing or eliminating the need for regular factor replacement therapy. HEMGENIX stands out for its pioneering gene therapy approach, presenting a transformative option for hemophilia B patients and potentially redefining the standard of care in this area.

In February 2024, Procuritas Capital Investors VII (Procuritas), a Sweden-based private equity fund, acquired Precision BioLogic (PBI) and its subsidiary Affinity Biologicals for an undisclosed amount. Through this acquisition, Procuritas aims to expand in the hemostasis diagnostics market by utilizing Precision BioLogic’s expertise in bleeding disorder testing, which includes assays for hemophilia A and B, inhibitor testing, and specialty coagulation reagents. Precision BioLogic is a Canada-based clinical-stage biotechnology company specializing in diagnostic assays and quality control products for bleeding disorders, forming a key part of its broader hemostasis diagnostics portfolio.

Major companies operating in the bleeding disorder testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Sysmex Corporation, Diagnostica Stago, Werfen Group, Sekisui Chemical Co. Ltd., Helena Laboratories, HORIBA Ltd., Mindray Medical International Limited, Nihon Kohden Corporation, Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Randox Laboratories Ltd., Haemonetics Corporation, QuidelOrtho Corporation, Instrumentation Laboratory, Beckman Coulter Inc., Grifols S.A., Meridian Bioscience Inc.

North America was the largest region in the bleeding disorder testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bleeding disorder testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bleeding disorder testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the bleeding disorder testing market by increasing costs of imported reagents, diagnostic instruments, automated analyzers, and specialized testing kits. Hospitals and diagnostic laboratories in North America and Europe are most affected due to dependence on imported laboratory equipment, while Asia-Pacific faces increased costs for manufacturing and exporting testing devices. These tariffs are raising testing costs and slowing laboratory upgrades. However, they are also driving domestic production of reagents, regional manufacturing of diagnostic instruments, and innovation in cost-efficient testing solutions.

The bleeding disorder testing market research report is one of a series of new reports that provides bleeding disorder testing market statistics, including bleeding disorder testing industry global market size, regional shares, competitors with a bleeding disorder testing market share, detailed bleeding disorder testing market segments, market trends and opportunities, and any further data you may need to thrive in the bleeding disorder testing industry. This bleeding disorder testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bleeding disorder testing involves a variety of diagnostic procedures designed to evaluate blood function and composition in order to detect abnormalities associated with bleeding disorders. These tests examine clotting ability, platelet function, and deficiencies or dysfunctions of specific clotting factors.

The primary product types in bleeding disorder testing are reagents and consumables, and instruments. The reagents and consumables segment of the bleeding disorder testing market includes the chemical substances, materials, and disposable items used in the analysis and diagnosis of bleeding disorders. This encompasses test kits, reagents, and other consumable supplies required to perform bleeding disorder tests. The indications covered include hemophilia A, hemophilia B, von Willebrand disease, idiopathic thrombocytopenic purpura, and others. Treatment approaches involve factor replacement therapy and drug therapy, and the tests are utilized by various end-users such as hospitals and clinics, diagnostic centers, and others.

The bleeding disorder testing market consists of revenues earned by entities by providing services such as complete blood count (CBC), prothrombin time (PT), activated partial thromboplastin time (aPTT), and genetic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The bleeding disorder testing market also includes sales of coagulation analyzers, platelet aggregation analyzers, blood collection devices, genetic testing kits, and bleeding time test kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.